The final, formatted version of the article will be published soon.
CASE REPORT article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 |
doi: 10.3389/fimmu.2025.1492296
This article is part of the Research Topic Early Detection, Cancer Interception, Et Al: Translating the Multifaceted Use of Liquid Biopsy to the Management of Early Disease View all 3 articles
Dynamics of blood microsatellite instability (bMSI) burden predicts outcome of a patient treated with immune checkpoint inhibitors: a case report of hyperprogressive disease
Provisionally accepted
Daria Kravchuk 1* Alexandra Lebedeva 2,3* Olesya Kuznetsova 2,4* Alexandra Kavun 2* Anastasiia Taraskina 2*
Ekaterina Belova 2,3,5 Tatiana Grigoreva 2,3* Egor Veselovsky 2* Vladislav Mileyko 2,3* Vladislav Nikulin 4* Lidia Nekrasova 6* Alexey Tryakin 4* Mikhail Fedyanin 1,4,7* Maxim Ivanov 2,3*- 1 State Budgetary Institution of Healthcare of the City of Moscow 'Moscow Multidisciplinary Clinical Center 'Kommunarka' of the Department of Health of the City of Moscow, Moscow, Moscow Oblast, Russia
- 2 OncoAtlas, LLC, Moscow, Russia
- 3 I.M. Sechenov First Moscow State Medical University, Moscow, Moscow Oblast, Russia
- 4 Russian Cancer Research Center NN Blokhin, Moscow, Moscow Oblast, Russia
- 5 Lomonosov Moscow State University, Moscow, Moscow, Russia
- 6 P.Herzen Moscow Oncology Research Institute (MORI), Moscow, Moscow Oblast, Russia
- 7 N.I. Pirogov National Medical and Surgical Center (NMSC), Moscow, Moscow Oblast, Russia
Microsatellite instability (MSI) is a widely studied molecular signature, which is associated with longterm benefit in patients treated with immune checkpoint inhibitor therapy. This approach has been proven to be effective in the treatment of patients with MSI-positive colorectal cancer (CRC). Analysis of serial liquid biopsy samples allows to detect changes in the tumor in response to therapy. Typically, somatic mutations are used for tracing the dynamics of the tumor, and the assessment of DNA signatures such as MSI is not currently used for these purposes. Here, we describe a case of a MSIpositive CRC, who received nivolumab monotherapy. Sequential sampling of the patient's plasma demonstrated an increase in MSI burden (bMSI), which was found to correlate with the increase of driver mutation burden one month after starting nivolumab, and hyperprogressive disease. Thus, analysis of bMSI in liquid biopsy via NGS may be a promising method for timely assessment of the treatment effectiveness received by patients with MSI-positive CRC.
Keywords: colorectal cancer, liquid biopsy, hyperprogression, Next-generation sequencing, dMMR
Received: 06 Sep 2024; Accepted: 16 Jan 2025.
Copyright: © 2025 Kravchuk, Lebedeva, Kuznetsova, Kavun, Taraskina, Belova, Grigoreva, Veselovsky, Mileyko, Nikulin, Nekrasova, Tryakin, Fedyanin and Ivanov. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Daria Kravchuk, State Budgetary Institution of Healthcare of the City of Moscow 'Moscow Multidisciplinary Clinical Center 'Kommunarka' of the Department of Health of the City of Moscow, Moscow, Moscow Oblast, Russia
Alexandra Lebedeva, OncoAtlas, LLC, Moscow, Russia
Olesya Kuznetsova, OncoAtlas, LLC, Moscow, Russia
Alexandra Kavun, OncoAtlas, LLC, Moscow, Russia
Anastasiia Taraskina, OncoAtlas, LLC, Moscow, Russia
Tatiana Grigoreva, OncoAtlas, LLC, Moscow, Russia
Egor Veselovsky, OncoAtlas, LLC, Moscow, Russia
Vladislav Mileyko, OncoAtlas, LLC, Moscow, Russia
Vladislav Nikulin, Russian Cancer Research Center NN Blokhin, Moscow, 115478, Moscow Oblast, Russia
Lidia Nekrasova, P.Herzen Moscow Oncology Research Institute (MORI), Moscow, 125284, Moscow Oblast, Russia
Alexey Tryakin, Russian Cancer Research Center NN Blokhin, Moscow, 115478, Moscow Oblast, Russia
Mikhail Fedyanin, Russian Cancer Research Center NN Blokhin, Moscow, 115478, Moscow Oblast, Russia
Maxim Ivanov, OncoAtlas, LLC, Moscow, Russia
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.